Page URL:

Ovarian cancer drug could treat BRCA-related breast cancer

12 June 2017
Appeared in BioNews 904

A drug treatment for ovarian cancer has shown success against inherited breast cancer.

Patients showed improved survival and decreased disease relapse after receiving olaparib, a drug used to treat ovarian cancer in women who carry BRCA1 or BRCA2 mutations.

'It is a perfect example of how understanding a patient's genetics and the biology of their tumour can be used to target its weaknesses and personalize treatment,' said Professor Andrew Tutt, director of the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, who was not involved in the study. 'Olaparib is already available for women with BRCA-mutant advanced ovarian cancer, and is the first drug to be approved that is directed against an inherited genetic mutation.'

Olaparib belongs to a class of drugs called PARP-inhibitors that act against proteins involved in DNA repair. Inherited BRCA mutations, which occur in up to three percent of all breast cancers, can impair the normal function of DNA repair by favouring abnormal cell growth, and so increase the risk of cancer.

In the OlumpiAD trial, carried out at the Memorial Sloan Kettering Cancer Center, New York, olaparib was given to 302 women who had metastatic breast cancer caused by BRCA mutations. The treatment led to tumour shrinkage in 60 percent of women, compared with only 29 percent of those treated with standard chemotherapy. After a median follow-up of 14 months, 42 percent of women showed slower cancer progression.

Researchers said the results were too preliminary to state whether patients could really benefit from olaparib treatment in terms of extended life. However, side effects such as hair loss and low white blood cell counts were reduced and only 37 percent of the patients experienced serious side effects compared with 50 percent for chemotherapy, demonstrating a better health-related quality of life.

'This is the first demonstration of improved outcomes with a PARP inhibitor compared to standard treatment in women with BRCA mutation-associated breast cancer,' said lead study author Dr Mark Robson of Memorial Sloan Kettering Cancer Center, New York. 'It is especially encouraging to see that olaparib was effective against triple negative breast cancers that arise in women with inherited, germline BRCA mutations. This type of breast cancer is particularly difficult to treat and often affects younger women.'

The results were published in the New England Journal of Medicine and presented at the 2017 American Society of Clinical Oncology Annual Meeting.

AstraZeneca expects to seek approval for use of the drug in breast cancer toward the end of this year, and two more trials will investigate potential applications of olaparib in patients with other types of breast cancer.

AstraZeneca's Lynparza slows advanced breast cancer progression: study
Reuters |  4 June 2017
New therapy offers hope against incurable form of breast cancer
The Guardian |  6 June 2017
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
New England Journal of Medicine |  4 June 2017
Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer
American Society of Clinical Oncology |  4 June 2017
Ovarian cancer drug reduces chance certain advanced breast cancers will get worse
Cancer Research UK |  4 June 2017
10 May 2021 - by Emma Bunting 
New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...
29 May 2018 - by Martha Henriques 
A virus has been reprogrammed to attack ovarian cancer cells in mice, effectively destroying tumours...
21 May 2018 - by Christie Whitehouse 
A new study indicates that an important drug used to treat breast cancer is just as effective when the course of treatment is shortened by half.
14 May 2018 - by Hannah Tippett Simpson 
DNA mutations that give tumours resistance to a new class of breakthrough breast and ovarian cancer drugs have been discovered...
8 May 2018 - by Dr James Heather 
Genetic testing could reveal a subset of patients with aggressive breast cancer who would benefit from a non-standard treatment, a clinical trial has found...
30 May 2017 - by Shaoni Bhattacharya 
The first cancer drug based on a specific genetic feature has been approved by the US drugs regulator...
20 March 2017 - by Dr Molly Godfrey 
A genetic study of breast cancer patients suggests that existing drugs for treating rare breast and ovarian cancers may help more patients than previously thought...
11 July 2016 - by Antony Starza-Allen 
Genetic mutations on several genes including BRCA2 have been associated with prostate cancer; while in a separate study, a BRCA1 mutation has been linked to a particular form of uterine cancer...
2 November 2015 - by Dr Jane Currie 
A drug that targets genetic mutations in ovarian cancer has been found to work in men with prostate cancer with similar mutations, according to a new study...
29 June 2009 - by Dr Rebecca Robey 
A new drug for the treatment of inherited forms of breast, ovarian and prostate cancer has shown promising results in early clinical trials. The study, published in the New England Journal of Medicine, reported that the drug promoted tumour reduction and clinical improvement in advanced-stage cancer patients whilst causing fewer side effects than conventional chemotherapy....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.